How Close are We to Having Structure-Modifying Drugs Available?
How Close are We to Having Structure-Modifying Drugs Available?
复制标题
DOI：
10.1016/j.mcna.2008.07.011
复制
发表时间：
2009-01-01
影响因子：
5.9
通讯作者：
Le Graverand-Gastineau, Marie-Pierre Hellio
中科院分区：
文献类型：
--
作者：
Hunter, David J.;Le Graverand-Gastineau, Marie-Pierre Hellio
本文综述了改善骨关节炎疾病的药物（DMOAD）的潜力，区分预防、延缓、停止和逆转疾病以及可能具有临床意义的药物。作者还描述了是否有任何证据表明可以改变疾病，以及目前主要关注的组织，即软骨，是否是一个合适的目标。方法学的方法和其他障碍，以证明这些药物在临床试验中的疗效被认为是。这一讨论是对一个迅速发展的领域的叙述性审查。希望读者能够理解该领域的复杂性以及DMOAD发展的可能道路。
This review describes the potential of disease-modifying osteoarthritis drugs (DMOADs), distinguishing between preventing, retarding, stopping, and reversing disease and what might be clinically meaningful. The authors also describe whether there is any evidence to suggest that one can modify disease, and whether the current tissue that is predominantly focused on, namely, cartilage, is an appropriate target. The methodologic approaches and other obstacles to demonstrating efficacy of these agents in clinical trials are considered. This discussion is a narrative review in a field that is rapidly evolving. It is hoped the reader appreciates the complexity of the field and the likely road ahead to DMOAD development.